Adarotene
Based on 14 publication(s) in Google Scholar
Adarotene is an effective apoptosis inducer, which surprisingly produces DNA damage and exhibites a potent antiproliferative activity on a large panel of human tumor cells.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.15%
- CAS No.: 496868-77-0
- 화학식: C25H26O3
- 분자량:374.47
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
용액&용해도
- Protocol
- 순도&문서
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Blood Cancer Compound Library
HY-L079
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Adarotene
More- Science. 2026 Feb 26;391(6788):eadz3121. [Abstract]
- Nat Biotechnol. 2025 Jul;43(7):1101-1115. [Abstract]
- Nat Commun. 2025 Jul 1;16(1):5706. [Abstract]
- Nat Commun. 2024 Aug 27;15(1):7375. [Abstract]
- Genes Dev. 2021 Oct 1;35(19-20):1356-1367. [Abstract]
- Biomed Pharmacother. 2020 Aug;128:110291. [Abstract]
- Cell Rep. 2020 Feb 18;30(7):2416-2429.e7. [Abstract]
- Int J Mol Sci. 2025 May 13;26(10):4651. [Abstract]
- Nanomaterials. 2024 Aug 23;14(17):1380. [Abstract]
- J Neuroimmune Pharmacol. 2025 May 8;20(1):52. [Abstract]
- Cell Physiol Biochem. 2017;41(2):519-529. [Abstract]
- bioRxiv. 2025 Nov 13.
- bioRxiv. 2024 Apr 25.
- Patent. US20200190009A1
Customer Validation & Images
-
WB
-
IF
-
Cell Proliferation/Viability Assay
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
0.1 μM
Compound: 4
|
Antiproliferative effect of compound on A2780/DX cell line
Antiproliferative effect of compound on A2780/DX cell line
|
[PMID: 12620066] |
| A-431 | IC50 |
0.12 μM
Compound: 1
|
Antiproliferative activity against human A431 cells incubated for 24 hrs drug exposure measured after 48 hrs of recovery by sulforhodamine B assay
Antiproliferative activity against human A431 cells incubated for 24 hrs drug exposure measured after 48 hrs of recovery by sulforhodamine B assay
|
[PMID: 22365912] |
| A-431 | IC50 |
0.25 μM
Compound: 4
|
Antiproliferative effect of compound on A431 cell line expressing mutant p53
Antiproliferative effect of compound on A431 cell line expressing mutant p53
|
[PMID: 12620066] |
| COS-7 | EC50 |
0.1 μM
Compound: 2
|
Effective concentration against retinoic acid receptor gamma in COS-7 cells co-expressing DR5-tk-CAT reporter; value range (0.1-0.3)
Effective concentration against retinoic acid receptor gamma in COS-7 cells co-expressing DR5-tk-CAT reporter; value range (0.1-0.3)
|
[PMID: 16033272] |
| COS-7 | EC50 |
0.2 μM
Compound: 2
|
Effective concentration against retinoic acid receptor alpha in COS-7 cells co-expressing DR5-tk-CAT reporter; value range (0.1-0.4)
Effective concentration against retinoic acid receptor alpha in COS-7 cells co-expressing DR5-tk-CAT reporter; value range (0.1-0.4)
|
[PMID: 16033272] |
| COS-7 | EC50 |
0.2 μM
Compound: 2
|
Effective concentration against retinoic acid receptor beta in COS-7 cells co-expressing DR5-tk-CAT reporter; value range (0.1-0.3)
Effective concentration against retinoic acid receptor beta in COS-7 cells co-expressing DR5-tk-CAT reporter; value range (0.1-0.3)
|
[PMID: 16033272] |
| DU-145 | IC50 |
0.1 μM
Compound: 4
|
Antiproliferative effect of compound on DU145 cell line expressing mutant p53
Antiproliferative effect of compound on DU145 cell line expressing mutant p53
|
[PMID: 12620066] |
| GBM | IC50 |
0.18 μM
Compound: 4
|
Antiproliferative effect of compound on GBM cell line expressing mutant p53
Antiproliferative effect of compound on GBM cell line expressing mutant p53
|
[PMID: 12620066] |
| HCT-116 | IC50 |
0.32 μM
Compound: 4
|
Antiproliferative effect of compound on HCT116 cell line expressing wild-type p53
Antiproliferative effect of compound on HCT116 cell line expressing wild-type p53
|
[PMID: 12620066] |
| IGROV-1 | IC50 |
0.23 μM
Compound: 1, ST1926
|
Antiproliferative activity against human IGROV1 cells after 72 hrs
Antiproliferative activity against human IGROV1 cells after 72 hrs
|
[PMID: 17512204] |
| IGROV-1 | IC50 |
0.23 μM
Compound: 2
|
Concentration of compound required for inhibition of (IGROV-1) human ovarian carcinoma cell growth by 50%
Concentration of compound required for inhibition of (IGROV-1) human ovarian carcinoma cell growth by 50%
|
[PMID: 16033272] |
| IGROV-1 | IC50 |
0.23 μM
Compound: 4
|
Antiproliferative effect of compound on IGROV-1 cell line expressing wild-type p53
Antiproliferative effect of compound on IGROV-1 cell line expressing wild-type p53
|
[PMID: 12620066] |
| IGROV-1 | IC50 |
0.4 μM
Compound: 1, ST1926
|
Antiproliferative activity against human cisplatin-resistant IGROV1/Pt1 cells with p53 mutation after 72 hrs
Antiproliferative activity against human cisplatin-resistant IGROV1/Pt1 cells with p53 mutation after 72 hrs
|
[PMID: 17512204] |
| LNCaP | IC50 |
0.12 μM
Compound: 4
|
Antiproliferative effect of compound on LNcaP cell line expressing wild-type p53
Antiproliferative effect of compound on LNcaP cell line expressing wild-type p53
|
[PMID: 12620066] |
| LoVo | IC50 |
0.15 μM
Compound: 4
|
Antiproliferative effect of compound on LoVo cell line expressing wild-type p53
Antiproliferative effect of compound on LoVo cell line expressing wild-type p53
|
[PMID: 12620066] |
| Me665/2/21 | IC50 |
0.25 μM
Compound: 4
|
Antiproliferative effect of compound on Me665/2/21 cell line expressing mutant p53
Antiproliferative effect of compound on Me665/2/21 cell line expressing mutant p53
|
[PMID: 12620066] |
| NB-4 | IC50 |
0.082 μM
Compound: 1, ST1926
|
Antiproliferative activity against human NB4 cells after 72 hrs
Antiproliferative activity against human NB4 cells after 72 hrs
|
[PMID: 17512204] |
| NB-4 | IC50 |
0.082 μM
Compound: 2
|
Concentration of compound required for inhibition of (NB4) human promyelocytic leukemia cell growth by 50%
Concentration of compound required for inhibition of (NB4) human promyelocytic leukemia cell growth by 50%
|
[PMID: 16033272] |
| NCI-H460 | IC50 |
0.19 μM
Compound: 4
|
Antiproliferative effect of compound on H460 cell line expressing wild-type p53
Antiproliferative effect of compound on H460 cell line expressing wild-type p53
|
[PMID: 12620066] |
| NCI-H460 | IC50 |
0.2 μM
Compound: 1
|
Antiproliferative activity against human NCI-H460 cells incubated for 24 hrs drug exposure measured after 48 hrs of recovery by sulforhodamine B assay
Antiproliferative activity against human NCI-H460 cells incubated for 24 hrs drug exposure measured after 48 hrs of recovery by sulforhodamine B assay
|
[PMID: 22365912] |
| PC-3 | IC50 |
0.21 μM
Compound: 4
|
Antiproliferative effect of compound on PC3 cell line
Antiproliferative effect of compound on PC3 cell line
|
[PMID: 12620066] |
| SAOS-2 | IC50 |
0.25 μM
Compound: 4
|
Antiproliferative effect of compound on SAOS cell line
Antiproliferative effect of compound on SAOS cell line
|
[PMID: 12620066] |
| U2OS | IC50 |
0.26 μM
Compound: 4
|
Antiproliferative effect of compound on U2OS cell line expressing wild-type p53
Antiproliferative effect of compound on U2OS cell line expressing wild-type p53
|
[PMID: 12620066] |
Adarotene causes a dose-dependent growth inhibition in a large panel of human tumor cell lines with IC50 ranging from 0.1 to 0.3 μM. Adarotene causes cell accumulation in G1/S or S phase of cell cycle depending on tumor cells IGROV-1 and DU145[1]. Adarotene is apoptotic and cytotoxic on a large spectrum of cancerous and leukemic cells, including freshly isolated AML blasts in primary culture. The molecular target of ST1926 apoptotic activity in myeloid leukemia cells is similar to the ligand-binding domain of RARγ. Adarotene treatment of cells results in rapid accumulation of intracellular calcium[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 496868-77-0
-
Appearance Solid
-
분자량 374.47
-
화학식 C25H26O3
-
Color White to green
-
SMILES
O=C(O)/C=C/C1=CC=C(C2=CC=C(O)C(C3(C4)CC5CC4CC(C5)C3)=C2)C=C1
-
Synonyms
ST1926
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (14)
-
Journal Impact Factor
-
Most Recent
-
Science
Different repair pathways support intact or truncated insertions by R2 retrotransposon protein. [Abstract]2026 Feb 26;391(6788):eadz3121. PMID: 41231928 -
Nat Biotechnol
2025 Jul;43(7):1101-1115. PMID: 39375448 -
Nat Commun
DNA polymerase α/primase extraction from chromatin by VCP/p97 restricts ATR activation during unperturbed DNA replication. [Abstract]2025 Jul 1;16(1):5706. PMID: 40593507 -
Nat Commun
DNA polymerase α-primase facilitates PARP inhibitor-induced fork acceleration and protects BRCA1-deficient cells against ssDNA gaps. [Abstract]2024 Aug 27;15(1):7375. PMID: 39191785 -
Genes Dev
2021 Oct 1;35(19-20):1356-1367. PMID: 34503990 -
Biomed Pharmacother
2020 Aug;128:110291. PMID: 32526455
Adarotene purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Aug;128:110291. [Abstract]
Western blot analysis of p-AMPKα, p-mTOR and p-P70S6K in ST1962 (2.5, 5 and 10 μM)-treated glioma cell lines for 24 h. AMPKα activation is markedly induced by ST1926 in a dose-dependent manner; phosphorylated mechanistic target of rapamycin (mTOR) and P70S6K expression levels are obviously down-regulated.
Adarotene purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Aug;128:110291. [Abstract]
Effects of ST1926 on retinoic acid (RA) pathway. Glioma cells are treated with ST1926 (2.5, 5 and 10 μM) for 24 h, immunofluorescence staining of CRABP2.
-
Cell Rep
2020 Feb 18;30(7):2416-2429.e7. PMID: 32075739 -
Int J Mol Sci
Exploring the Anti-Leukemic Effect of the Synthetic Retinoid ST1926 on Malignant T Cells: A Comprehensive Proteomics Approach. [Abstract]2025 May 13;26(10):4651. PMID: 40429796 -
Nanomaterials
Novel ST1926 Nanoparticle Drug Formulation Enhances Drug Therapeutic Efficiency in Colorectal Cancer Xenografted Mice. [Abstract]2024 Aug 23;14(17):1380. PMID: 39269042 -
J Neuroimmune Pharmacol
HucMSCs-Derived Extracellular Vesicles Deliver RPS27A Protein to Manipulate the MDM2-P53 Axis and Ameliorate Neurological Dysfunction in Parkinson's Disease. [Abstract]2025 May 8;20(1):52. PMID: 40338442 -
Cell Physiol Biochem
2017;41(2):519-529. PMID: 28214860
Adarotene purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2017;41(2):519-529. [Abstract]
Arithmetic means±SEM (n=10) of erythrocyte annexin-V-binding following incubation for 48 hours to Ringer solution without (white bar) or with (black bars) Adarotene (3-9 µM) or solvant DMSO alone (grey bar).
-
-
-
용액&용해도
DMSO : 25 mg/mL (66.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.68 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.68 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Briefly, cells (1×107/mL) are loaded with 1 μM FURA-2 at 37°C in the dark for 30 minutes, washed twice, resuspended in phosphate-buffered saline (PBS) containing 1.26 mM CaCl2 at 106 cells/mL and then used for the experiments. Dual excitation, alternating at 340 nm and 380 nm, is provided by a spectrophotofluorometer equipped with 2 excitation monochromators, and emission is fixed at 480 nm. The temperature is set at 37°C±1°C. In some experiments, to eliminate extracellular calcium, cells preloaded with FURA-2 are resuspended in PBS without Ca2+, and 0.5 mM EGTA (ethylene glycol tetraacetic acid) is added to each sample prior to addition of the appropriate stimulus.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
NB4 cells (3×106) are intraperitoneally inoculated in SCID mice (8 mice/group). ST1926 is dissolved in cremophor/ethanol 1:1 solution, and diluted 1:10 in PBS at the concentration of 50 mg/kg; the doses of 30 mg/kg and 40 mg/kg are then prepared by appropriate dilutions in the same vehicle. ATRA is dissolved in the dark in Cremophor EL and kept magnetically stirred; the solution is then diluted 1:10 in PBS at the final concentration of 40 mg/kg. Both compounds are administered intraperitoneally and orally twice per day for 3 weeks starting from the day after cell inoculation, in a volume of 10 mL/kg. During treatments body weight and lethality are registered.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
순도&문서
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Cincinelli R, et al. A novel atypical retinoid endowed with proapoptotic and antitumor activity. J Med Chem. 2003 Mar 13;46(6):909-12. [Content Brief]
[2]. Garattini E, et al. ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells: modulation of intracellular calcium homeostasis. Blood. 2004 Jan 1;103(1):194-207. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6704 mL | 13.3522 mL | 26.7044 mL | 66.7610 mL |
| 5 mM | 0.5341 mL | 2.6704 mL | 5.3409 mL | 13.3522 mL | |
| 10 mM | 0.2670 mL | 1.3352 mL | 2.6704 mL | 6.6761 mL | |
| 15 mM | 0.1780 mL | 0.8901 mL | 1.7803 mL | 4.4507 mL | |
| 20 mM | 0.1335 mL | 0.6676 mL | 1.3352 mL | 3.3381 mL | |
| 25 mM | 0.1068 mL | 0.5341 mL | 1.0682 mL | 2.6704 mL | |
| 30 mM | 0.0890 mL | 0.4451 mL | 0.8901 mL | 2.2254 mL | |
| 40 mM | 0.0668 mL | 0.3338 mL | 0.6676 mL | 1.6690 mL | |
| 50 mM | 0.0534 mL | 0.2670 mL | 0.5341 mL | 1.3352 mL | |
| 60 mM | 0.0445 mL | 0.2225 mL | 0.4451 mL | 1.1127 mL |
Powered by Bioz